Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 651 - 675 of 14983 in total

Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated

Approved
Matched Mixtures name: … DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEA …

Vibrio cholerae Inaba 48 classical biotype, heat inactivated

Approved
Matched Mixtures name: … DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEA …

Cefpiramide

Cefpiramide is a third-generation cephalosporin antibiotic.
Approved
Matched Iupac: … methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Salts name: … Cefpiramide sodium …

Eplontersen

Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery. It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of...
Approved
Investigational
Matched Description: … thus accumulation of insoluble and misfolded amyloid in multiple organs, although wild-type misfolded ... [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment ... NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS+7) and …
Matched Salts name: … Eplontersen sodium …

Dichromate

Approved
Investigational

Icatibant

Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B2 receptors antagonists, thus representing a new class of medication.[A4017,A263041] It was...
Approved
Investigational
Matched Description: … Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the Band has a potency of 2-3 times higher than ... [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Dienogest

Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not...
Approved
Matched Description: … Dienogest is commonly marketed as Visanne, Natazia and Qlaira. ... It is a derivative of 19-nortestosterone and has antiandrogenic properties. ... in combination with ethinylestradiol, or in other combination form pills approved in United States and …
Matched Mixtures name: … Estradiol Valerate and Estradiol Valerate/Dienogest ... Estradiol Valerate and Estradiol Valerate/Dienogest …
Matched Categories: … dienogest and estrogen ... dienogest and estradiol ... dienogest and ethinylestradiol ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System …

Gonadorelin

Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Approved
Investigational
Vet approved
Matched Description: … GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Gonadotropins and Antigonadotropins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Nafarelin

Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Approved
Matched Description: … Nafarelin has been used in the treatments of central precocious puberty and endometriosis. …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Gonadotropins and Antigonadotropins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Ramucirumab

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … , and migration of human endothelial cells. ... By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby ... VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Revefenacin

Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LAMA group falls into a...
Approved
Investigational
Matched Description: … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] ... The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type ... labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and …

Dextrothyroxine

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum...
Approved
Investigational
Matched Iupac: … (2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid …
Matched Description: … Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. ... Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines …
Matched Salts name: … Dextrothyroxine sodium …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Difelikefalin

Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. Further investigations revealed that dynorphins, endogenous agonists of KORs, work to inhibit the itching sensation at the spinal cord level, and...
Approved
Investigational
Matched Iupac: … amino-3-phenylpropanamido]-3-phenylpropanamido]-4-methylpentanamido]hexanoyl]piperidine-4-carboxylic acid …
Matched Description: … with chronic kidney disease (also called uremic pruritus) affects 50-60% of all patients on dialysis and ... dynorphins, endogenous agonists of KORs, work to inhibit the itching sensation at the spinal cord level, and ... therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and …

Ropinirole

Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first...
Approved
Investigational
Matched Description: … Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and ... offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711]. ... capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and …

Dihydroergotamine

A 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing...
Approved
Investigational
Matched Description: … use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and ... technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and …
Matched Categories: … Ergot Alkaloids and Derivatives …

Fluticasone furoate

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Approved
Matched Description: … Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various …
Matched Mixtures name: … Fluticasone Furoate and Vilanterol ... Fluticasone Furoate and Vilanterol …
Matched Categories: … vilanterol and fluticasone furoate ... vilanterol, umeclidinium bromide and fluticasone furoate …

Menadione

A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Approved
Nutraceutical
Matched Description: … A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted …
Matched Categories: … Blood and Blood Forming Organs ... Diet, Food, and Nutrition …

Dalbavancin

Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]....
Approved
Investigational
Matched Description: … S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. ... Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ... antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Filgrastim

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human...
Approved
Matched Description: … It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous ... [L40719] It has a number of therapeutic uses, including the management and prevention of infections and ... G-CSF and has an N-terminal methionine added in the sequence for expression in _E. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Enasidenib

Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment...
Approved
Investigational
Matched Description: … Food and Drug Administration on August 1, 2017. ... First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. ... This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Lisuride

An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Approved
Investigational
Matched Description: … It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors …
Matched Categories: … Ergot Alkaloids and Derivatives ... Genito Urinary System and Sex Hormones …

Cefpodoxime

Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Approved
Vet approved
Matched Iupac: … 2-(methoxyimino)acetamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. ... is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and ... Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug …
Matched Salts name: … Cefpodoxime sodium …

Pimecrolimus

Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Approved
Investigational
Matched Categories: … Skin and Mucous Membrane Agents …

Carfilzomib

Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Approved
Investigational
Matched Description: … Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Zoledronate D,L-Lysine Monohydrate

Approved
Investigational
Matched Iupac: … 2,6-diaminohexanoic acid [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid hydrate …
Displaying drugs 651 - 675 of 14983 in total